Clinical Trial

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

Name: Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C — clinical trial record (NCT05631249)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CODEBREAK-IGR

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2022-11-21; most recent amendment 2025-05-07.

Trial Details

NCT Number	NCT05631249
Lead Sponsor	Gustave Roussy, Cancer Campus, Grand Paris
Conditions	KRAS P.G12C, Non Small Cell Lung Cancer
Enrollment	40 participants
Start Date	2022-12-13
Primary Completion	2027-12-12 (estimated)
Study Completion	2027-12-12 (estimated)
Updated on ClinicalTrials.gov	2025-05-08